Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2012

01-10-2012 | Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

Chronic Osteomyelitis

Authors: Ilker Uçkay, Kheeldass Jugun, Axel Gamulin, Joe Wagener, Pierre Hoffmeyer, Daniel Lew

Published in: Current Infectious Disease Reports | Issue 5/2012

Login to get access

Abstract

Chronic osteomyelitis is a multifaceted bacterial infection with common features. It absolutely requires surgery for remission. The duration and form of concomitant administration of antibiotic agents for adult patients is still based on expert opinion. The traditional recommendation of 6–12 weeks of antibiotic therapy, where, for at least the first 2–6 weeks, antibiotics should be administered intravenously, is more and more challenged in favor of an oral antibiotic treatment with selected agents from the start. There is no evidence that the total duration of antibiotic therapy for more than 4–6 weeks improves outcome, when compared with shorter regimens. Hopefully, the future will show randomized trials in the adult population, allowing optimal timing of surgical and medical therapy and sparing of unnecessary prescription, with concomitant development of antibiotic resistance. External advice from an expert team with combined surgeons and infectious disease physicians may help to reduce antibiotic consumption in a cost-effective way.
Literature
1.
Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9:127–38.PubMedCrossRef
2.
3.
Whitehouse JD, Friedman ND, Kirkland KB, et al. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol. 2002;23:183–9.PubMedCrossRef
4.
Uçkay I, Harbarth S, Peter R, et al. Preventing surgical site infections. Expert Rev Anti Infect Ther. 2010;8:657–70.PubMedCrossRef
5.
• Rod-Fleury T, Dunkel N, Assal M, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. Int Orthop. 2011;35:1725–31. Retrospective single-centre study regarding the optimal duration of antibiotic treatment concomitant to surgery in implant-free chronic osteomyelitis. Short regimens do not enhance recurrence risk.PubMedCrossRef
6.
•• Paakkonen M, Peltola H. Antibiotic treatment for acute haematogenous osteomyelitis of childhood: moving towards shorter courses and oral administration. Int J Antimicrob Agents. XXX,38:273–280. A state-of-the art paper concerning short antibiotic regimens for pediatric cases.
7.
8.
Cierny 3rd G, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7–24.PubMedCrossRef
9.
Legout L, Assal M, Rohner P, et al. Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis. 2006;38:728–30.PubMedCrossRef
10.
Blyth CC, Gomes L, Sorrell TC, et al. Skull-base osteomyelitis: fungal vs. bacterial infection. Clin Microbiol Infect. 2011;17:306–11.PubMedCrossRef
11.
• Uçkay I, Pittet D, Vaudaux P, et al. Foreign body infections due to Staphylococcus epidermidis. Ann Med. 2009;41:109–19. Clinical problems dealing with biofilms in implant-associated infections.PubMedCrossRef
12.
Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine. 2008;33:297–304.CrossRef
13.
Hernigou P, Daltro G, Flouzat-Lachaniette CH, et al. Septic arthritis in adults with sickle cell disease often is associated with osteomyelitis or osteonecrosis. Clin Orthop Relat Res. 2010;468:1676–81.PubMedCrossRef
14.
Al-Tawfiq JA. Bacteroides fragilis bacteremia associated with vertebral osteomyelitis in a sickle cell patient. Intern Med. 2008;47:2183–5.PubMedCrossRef
15.
Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis. 2010;14:752–8.CrossRef
16.
Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg. 2006;117:212–38.CrossRef
17.
Beals RK, Bryant RE. The treatment of chronic open osteomyelitis of the tibia in adults. Clin Orthop Relat Res. 2005;433:212–7.PubMedCrossRef
18.
Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76:479–83.PubMedCrossRef
19.
Hannan CM, Attinger CE. Special considerations in the management of osteomyelitis defects (diabetes, the ischemic or dysvascular bed, and irradiation). Semin Plast Surg. 2009;23:132–40.PubMedCrossRef
20.
•• Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54:393–407. Summary of antibiotic administration for osteomyelitis. Favors early switch to oral regimens.PubMedCrossRef
21.
Costerton W, Veeh R, Shirtliff M, et al. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466–77.PubMed
22.
Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–6.PubMed
23.
Lew D, Schrenzel J, François P, Vaudaux P. Pathogenesis, prevention, and therapy of staphylococcal prosthetic infections. Curr Clin Top Infect Dis. 2001;21:252–70.PubMed
24.
25.
Uçkay I, Ferry T, Stern R, et al. Use of serum antistreptolysin-O-titers in the microbial diagnosis of orthopedic infections. Int J Infect Dis. 2009;13:421–4.PubMedCrossRef
26.
Bernard L, Uçkay I, Vuagnat A, et al. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis. Int J Infect Dis. 2009;14:390–3.CrossRef
27.
Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978;239:2772–5.PubMedCrossRef
28.
29.
Boda A. Antibiotic irrigation-perfusion treatment for chronic osteomyelitis. Arch Orthop Trauma Surg. 1979;95:31–5.PubMedCrossRef
30.
Berendt T, Byren I. Bone and joint infection. Clin Med (London, England). 2004;4:510–8.
31.
Kınık H, Karaduman M. Cierny-Mader Type III chronic osteomyelitis: the results of patients treated with debridement, irrigation, vancomycin beads and systemic antibiotics. Int Orthop. 2008;32:551–8.PubMedCrossRef
32.
Tan Y, Wang X, Li H, et al. The clinical efficacy of the vacuum-assisted closure therapy in the management of adult osteomyelitis. Arch Orthop Trauma Surg. 2011;131:255–9.PubMedCrossRef
33.
Beckles VL, Jones HW, Harrison WJ. Chronic haematogenous osteomyelitis in children: a retrospective review of 167 patients in Malawi. J Bone Joint Surg Br. 2010;92:1138–43.PubMedCrossRef
34.
Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin Infect Dis. 2006;43:193–8.PubMedCrossRef
35.
Andel H, Felfernig M, Andel D, et al. Hyperbaric oxygen therapy in osteomyelitis. Anaesthesia. 1998;53:68–9.PubMedCrossRef
36.
Bernard L, Legout L, Zürcher-Pfund L, et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect. 2010;61:125–32.PubMedCrossRef
37.
•• Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2009;3:CD004439. Metaanalysis regarding antibiotic duration and administration form in adult chronic osteomyelitis.PubMed
38.
Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res. 1999;360:47–65.PubMedCrossRef
39.
Matthews PC, Conlon CP, Berendt AR, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? a retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;60:356–62.PubMedCrossRef
40.
Auh JS, Binns HJ, Katz BZ. Retrospective assessment of subacute or chronic osteomyelitis in children and young adults. Clin Pediatr. 2004;43:549–55.CrossRef
41.
Uçkay I, Lew DP. Infections in skeletal prostheses. In: Lippincott JW, editor. Bennet & Brachman’s hospital infections. Philadelphia: Williams & Wilkins; 2007. p. 665–72. 39.
42.
Smilack JD, Flittie WH, Williams Jr TW. Bone concentrations of antimicrobial agents after parenteral administration. Antimicrob Agents Chemother. 1976;9:169–71.PubMedCrossRef
43.
Daver NG, Shelburne SA, Atmar RL, et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect. 2007;54:539–44.PubMedCrossRef
44.
Dellamonica P, Bernard E, Etesse H, et al. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis. 1989;8:1024–30.PubMedCrossRef
45.
• Toma MB, Smith KM, Martin CA, Rapp RP. Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics. 2006;29:497–501. Pharmacokinetic considerations or oral antibiotics for treatment of osteomyelitis.PubMed
46.
Martini M, Adjrad A, Boudjemaa A. Tuberculous osteomyelitis. A review of 125 cases. Int Orthop. 1986;10:201–7.PubMed
47.
Abgueguen P, Pichard E, Aubry J. Buruli ulcer or Mycobacterium ulcerans infection. Med Mal Infect. 2010;40:60–9.PubMedCrossRef
48.
Landais C, Fenollar F, Constantin A, et al. Q fever osteoarticular infection: four new cases and a review of the literature. Eur J Clin Microbiol Infect Dis. 2007;26:341–7.PubMedCrossRef
49.
Uçkay I, Bouchuiguir-Wafa K, Ninet B, et al. Posttraumatic ankle arthritis due to a novel Nocardia species. Infection. 2010;38:407–12.PubMedCrossRef
50.
Sürücüoğlu S, El S, Ural S, et al. Evaluation of real-time PCR method for rapid diagnosis of brucellosis with different clinical manifestations. Pol J Microbiol. 2009;58:15–9.PubMed
51.
Gentry LO. Antibiotic therapy for osteomyelitis. Infect Dis Clin North Am. 1990;4:485–99.PubMed
52.
Lack W, McKinley T. Marjolin’s ulcer: incidental diagnosis of squamous cell carcinoma on hemipelvectomy for recalcitrant pelvic osteomyelitis. Iowa Orthop J. 2010;30:174–6.PubMed
53.
Eyichukwu GO, Anyaehie UE. Outcome of management of chronic osteomyelitis at National Orthopaedic Hospital, Enugu. Niger J Med. 2009;18:194–8.PubMed
54.
Uçkay I, Dinh A, Vauthey L, et al. Spondylodiscitis due to Propionibacterium acnes: report of twenty-nine cases and a review of the literature. Clin Microbiol Infect. 2010;16:353–8.PubMedCrossRef
55.
Salvana J, Rodner C, Browner BD, et al. Chronic osteomyelitis: results obtained by an integrated team approach to management. Conn Med. 2005;69:195–202.PubMed
56.
Mandell GL. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis. 1983;5:463–7.CrossRef
57.
Czekaj J, Dinh A, Moldovan A, et al. Efficacy of a combined oral clindamycin-rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis. 2011;43:962–7.PubMedCrossRef
58.
Uçkay I, Laurent F, Lustig S, et al. Hospital and community-acquired methicillin-resistant Staphylococcus aureus bone and joint infections. In: Kolendi CL, editor. Methicillin-resistant Staphylococcus aureus. Etiology, at-risk populations and treatment. New York: Nova Science Publishers; 2010. p. 143–209. 4.
59.
Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351–7.PubMedCrossRef
60.
Boffi El Amari E, Vuagnat A, Stern R, et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis. 2004;36:712–7.PubMed
61.
LeFrock JL, Ristuccia AM, Ristuccia PA, et al. Teicoplanin in the treatment of bone and joint infections. Eur J Surg Suppl. 1992;567:9–13.PubMed
62.
Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44:595–7.PubMedCrossRef
63.
Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41:341–53.CrossRef
64.
Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis. 2006;43:968–70.PubMedCrossRef
65.
Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–6.PubMedCrossRef
66.
Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599–602.PubMedCrossRef
67.
Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis. 2003;36:1197.PubMedCrossRef
68.
Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390–8.PubMed
69.
Gorwitz RJ JD, Powers JH, Jernigan JA. Strategies for clinical management of MRSA in the community: summary of an experts’ meeting convened by the Centers for Disease Control and Prevention. Washington, DC; 2006.
70.
Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:584–93.PubMedCrossRef
71.
Johnson MD, Decker CF. Antimicrobial agents in treatment of MRSA infections. Dis Mon. 2008;54:793–800.PubMedCrossRef
72.
Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F. Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus. J Clin Pathol. 1981;34:559–63.PubMedCrossRef
73.
Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents. 1999;12:79–93.CrossRef
74.
Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39:235–40.PubMedCrossRef
75.
Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999;12:35–44.CrossRef
76.
Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother. 2004;53:928–35.PubMedCrossRef
77.
Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46:1069–77.PubMedCrossRef
78.
Lew DP, Waldvogel FA. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs. 1999;58:85–91.PubMedCrossRef
79.
•• Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E. Oral antibiotics are effective for highly resistant hip arthroplasty infections. Clin Orthop Relat Res. 2009;467:2335–42. Feasibility of oral antibiotic regimens even for arthroplasty-related osteomyelitis.PubMedCrossRef
80.
Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother. 2000;44:164–6.PubMedCrossRef
81.
Nelson CL. The current status of material used for depot delivery of drugs. Clin Orthop Relat Res. 2004;427:72–8.PubMedCrossRef
82.
Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59:1223–32.PubMedCrossRef
83.
Walenkamp GH, Kleijn LL, de Leeuw M. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1–12 years. Acta Orthop Scand. 1998;69:518–22.PubMedCrossRef
84.
Uçkay I, Assal M, Legout L, et al. Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection. J Clin Microbiol. 2006;44:1194–6.PubMedCrossRef
85.
Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51:1261–8.PubMedCrossRef
86.
Panda M, Ntungila N, Kalunda M, Hinsenkamp M. Treatment of chronic osteomyelitis using the Papineau technique. Int Orthop. 1998;22:37–40.PubMedCrossRef
87.
Leone S, Borre S, Monforte A, et al. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis. 2010;14:67–77.CrossRef
88.
Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival. J Bone Joint Surg Br. 2001;83:403–7.PubMedCrossRef
89.
Siegel HJ, Patzakis MJ, Holtom PD, et al. Limb salvage for chronic tibial osteomyelitis: an outcomes study. J Trauma. 2000;48:484–9.PubMedCrossRef
90.
Seghrouchni K, van Delden C, Dominguez D, et al. Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study. Int Orthop. 2011;36:1065–71.
91.
Bauer T, David T, Rimareix F, Lortat-Jacob A. Marjolin’s ulcer in chronic osteomyelitis: seven cases and a review of the literature. Rev Chir Orthop Reparatrice Appar Mot. 2007;93:63–71.PubMedCrossRef
92.
• Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24:145–61. Everything you want to know about diabetic foot osteomyelitis.CrossRef
93.
Valabhji J, Oliver N, Samarasinghe D, et al. Conservative management of diabetic forefoot ulceration complicated by underlying osteomyelitis: the benefits of magnetic resonance imaging. Diabet Med. 2009;26:1127–34.PubMedCrossRef
94.
Byren I, Peters EJ, Hoey C, et al. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother. 2009;10:3033–47.PubMedCrossRef
95.
Venkatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med. 1997;14:487–90.PubMedCrossRef
96.
• Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51:962–7. Feasibility of conservative management of chronic diabetic toe osteomyelitis.PubMedCrossRef
97.
Uçkay I, Vernaz-Hegi N, Harbarth S, et al. Activity and impact on antibiotic use and costs of a dedicated infectious diseases consultant on a septic orthopaedic unit. J Infect. 2009;58:205–12.PubMedCrossRef
Metadata
Title
Chronic Osteomyelitis
Authors
Ilker Uçkay
Kheeldass Jugun
Axel Gamulin
Joe Wagener
Pierre Hoffmeyer
Daniel Lew
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2012
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0286-0

Other articles of this Issue 5/2012

Current Infectious Disease Reports 5/2012 Go to the issue

Sepsis (J Russell, Section Editor)

HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Subcutaneous Fungal Infections

Sepsis (J Russell, Section Editor)

Cardiovascular Management of Septic Shock in 2012

Sepsis (J Russell, Section Editor)

Immunoglobulins in Adult Sepsis and Septic Shock

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

From Ulcer to Infection: An Update on Clinical Practice and Adjunctive Treatments of Diabetic Foot Ulcers

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Septic Arthritis in the Native Joint
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits